if adverse reactions occur, discontinue use
GLP-1 Receptor Limb GLP-1R activation is the most extensively characterised pathway in this class
There are no specific contraindications, and the reduced venous thromboembolism risk seen in the Jorge study is particularly relevant for APS patients
Rather, it reveals predispositions in peptide hormone pathways, which should be interpreted alongside your clinical history, lab work, and cardiovascular assessment
To arrange a consultation with our medical director or for more information on our Intracellular Glutathione Therapy, please call 020 3095 0002 to speak to one of the team.
When GSH levels are low, this axis is inhibited, which indirectly inactivates GPX4